October 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
Neuropathic Pain
Basimglurant Fast Tracked for Pain Associated with Trigeminal Neuralgia
Basimglurant is a potent, cell-penetrant negative allosteric modulator of mGlu5 receptors that works by lowering the perception of pain threshold.
![HYQVIA (immune globulin [human] 10% with recombinant human hyaluronidase) by Baxter and Halozyme](https://www.empr.com/wp-content/uploads/sites/7/2018/12/hyqviaarticle_656631.png)
Hyqvia Reduces Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Trial
The ADVANCE-1 trial included adults with a confirmed diagnosis of CIDP who had remained on a stable dosing regimen of IVIG therapy for at least 3 months prior to screening.
FDA Clears PENS Device for Pain Related to Diabetic Peripheral Neuropathy
First Relief is a wearable PENS device that is placed behind the ear.
Topical Amitriptyline Gets Fast Track Status for Chemotherapy-Induced Neuropathic Pain
ATX01 is a topical formulation of amitriptyline designed to directly inhibit pain signaling in the nerve fibers on the epidermis and dermis.
Medtronic’s SCS Therapy Approved for Painful Diabetic Peripheral Neuropathy
These SCS devices were cleared based on data from a randomized controlled trial published in the journal Diabetes Care in 2014.
AAN: Painful Diabetic Neuropathy Treatment Guidelines Updated
Several pharmacotherapies have been shown to reduce pain in patients with painful diabetic neuropathy.
Enrollment in Fibromyalgia Treatment Study Ends After Disappointing Results
The phase 3 RALLY study is evaluating the efficacy and safety of TNX-102 SL in 514 adult patients with fibromyalgia.
FDA Approves Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy
Nevro’s SCS system for painful diabetic neuropathy will be available under the brand name HFX™ for PDN.
Capsaicin 8% Safe and Effective for Diabetic Peripheral Nerve Pain Therapy
Investigators assessed the efficacy and tolerability of a high-concentration capsaicin 8% patch to treat diabetic peripheral nerve pain, either alone or in combination with standard oral therapies.
